Strategic design is as vital as funding for early startup growth

Early-stage startups often fail during the transition from technology to business, a period known as the "Valley of Death." To overcome this, companies must integrate direct commercialization grants with indirect support, such as expert mentoring, to avoid wasting resources on unnecessary trials and errors.

The stage where early-stage startups fail most frequently is not during the initial creation of technology, but during the transition of that technology into a business. For an idea validated in a laboratory or a founder's mind to become a market-ready game changer, it must pass through several gates, including prototype production, customer validation, certification and licensing, initial sales, and follow-on investment. In this period, often referred to as the "Valley of Death," startups lack more than just capital; they also lack the experience and networks required to judge which gates to cross first and what must be proven at each stage.

In a previous column, it was noted that the core of supporting early-stage companies is "finding the unique bottleneck for each company." This article looks more specifically at accelerating programs, which serve as the means to resolve those bottlenecks. Accelerating can be broadly divided into programs that directly support commercialization and those that provide indirect support; how these two pillars interlock determines whether the same period and budget yield entirely different results.

Accelerating is "Compressing Time"

An accelerator is an institution that selects early-stage startups for intensive nurturing over a set period and, if necessary, makes direct investments. In South Korea, these entities operate as registered "Startup Accelerators" under the Small and Medium Enterprise Startup Support Act. Their role differs slightly from business incubators that simply provide office space, and from venture capital firms that focus primarily on supplying capital.

The essence of accelerating lies in compressing time. It aims to help founders make decisions within a few months that might otherwise take years of trial and error to learn alone. This is particularly critical in fields like healthcare, where clinical trials, licensing, insurance listing, and hospital procurement processes are intertwined; the cost of spending six months in the wrong direction is much higher than in other industries. Depending on how the licensing path is initially established, the required clinical evidence changes, which can alter development periods and necessary funding scales by years and hundreds of millions of won.

Direct Support: Commercialization Grants Should Be Used for "Proof"

A representative form of direct support is commercialization grants. This method provides funds through government startup support projects or nurturing programs commissioned by public institutions to be used for prototype production, testing, certification, demonstration, and marketing. For early-stage companies, this is significant because it provides capital without requiring the surrender of equity. While it is difficult to have a company's value recognized in the early stages, forcing investment can lead to heavy equity dilution; commercialization grants serve to fill that gap.

However, commercialization grants are funds with designated uses. They come with restrictions on expenditure items and periods, as well as requirements for settlement and performance reporting. Therefore, the priority is not the amount, but "what is being proven" with it. Some companies use the same grant to simply produce one more prototype, while others use that prototype to conduct usability evaluations or hospital demonstrations to create the evidence needed for the next investment review. The former has merely exhausted the grant, while the latter has used it as a stepping stone to move to the next stage.

For healthcare startups, this distinction becomes even clearer. There is data that, while expensive, must be verified by follow-on investors and partners, such as non-clinical trials, performance evaluations, medical device testing, and usability evaluations. If commercialization grants are focused on securing this "basis for judgment," the company will possess assets that remain even after the support period ends.

Indirect Support: Does Not Convert to Cash but Reduces Trial and Error

Indirect support refers to programs that do not provide direct funds but assist in decision-making and provide practical networks, such as consulting, expert mentoring, networking, IR and demo days, and links to follow-on investment. Although these results may not be immediately visible in numbers and can sometimes be overlooked, they are often more decisive for early-stage companies.

For example, a one-hour meeting with a licensing expert can correct a product's classification and licensing path, thereby avoiding unnecessary clinical trials. A review by a patent expert can expand the scope of rights for core technology, increasing bargaining power in future technology transfer negotiations. Connections with hospitals, pharmaceutical companies, or open innovation managers at large corporations can expedite a first meeting that would otherwise take a founder months to arrange alone. Feedback received during investment preparation can also lead to restructuring the numbers in a business plan to align with investor questions.

The value of indirect support lies in reducing "things that do not need to be done." For early-stage companies with limited resources, deciding what not to do is as important as deciding what to do, and those decisions usually stem from the experience of those who have already walked the same path.

The Two Pillars are Partners, Not Substitutes

A common disappointing scene in the field is when these two pillars operate separately. If there is only funding without direction, the money is exhausted according to the items listed in the plan but does not lead to the next stage. Conversely, if there is only consulting and mentoring without the funds to execute, time passes without the ability to actually generate data or conduct demonstrations, despite having received good advice.

Well-designed accelerating binds two axes into a single flow. First, it diagnoses the company's current stage and bottlenecks, then determines what must be proven at the next milestone. The costs required for that proof are executed through commercialization support funds, while the design of that proof—namely, which metrics to secure and according to whose standards—is refined through expert consulting. Then, the results are connected to investors, hospitals, and corporate partners through networking. For example, in the case of hospital validation for a medical device company, the validation costs are covered by support funds, the task of aligning the validation protocol with hospital procurement officers and regulatory requirements is handled through consulting, and the touchpoint for moving into procurement discussions or joint research after validation is filled through networking.

Let's look at how this two-track design actually works through the case of M Tech Lab. M Tech Lab, led by CEO Baek Hyeon-man, is an MRI-based medical imaging technology company based in Songdo, Incheon. While providing MRI image analysis services such as brain region segmentation, functional MRI, and diffusion MRI, they are also developing a product line of genomic pads that improve image quality during MRI scans for various body parts, and are conducting R&D in the field of electroceuticals.

As is common for early-stage medical device companies, M Tech Lab faced two challenges simultaneously: the research capabilities and infrastructure to advance product performance and evidence, and a channel to connect those results to investment and financing.

J&P Medi Partners connected these two challenges through different tracks. First, through the R&D track, they supported technological advancement by linking the company with the Inha University Open Lab. Simultaneously, through the accelerating track, they supported preparations for investment attraction, such as IR advancement, matching with professional investment institutions, and demo days, by linking them to the Korea Health Industry Development Institute's specialized investment institution-linked investment attraction support program. One was the task of creating 'things to prove,' and the other was the task of translating that proof into 'the language of investors.'

As a result of these two tracks interlocking, M Tech Lab was selected for TIPS (Tech Incubator Program for Startups), a private-investment-led technology startup support program, upon the recommendation of the fund operated by J&P Medi Partners as a Co-GP. Since TIPS is a structure where private investment and government R&D funds are combined, a technology must possess both technical completeness and verification from investors. If there had been only R&D support, the technology might have improved, but it would have been difficult to lead to investment attraction; if there had been only investment attraction support, there would have been a lack of evidence to persuade investors and evaluation institutions. This is precisely what was meant by saying that direct support and indirect support must work as a 'pair.'

Good accelerating is not about running on behalf of a startup, but about lighting the path so that the startup can run the same distance with fewer trials and errors. Commercialization support funds become the fuel to run that path, while consulting and networks become the map that provides direction. Only when both are equipped can one finally run quickly toward the correct destination.

Read the original (Korean)